December 16, 2014 | The Israeli company BrainStorm Cell Therapeutics, a developer of stem cell treatments for neurodegenerative diseases, announced that it was awarded a grant of $1.1 million from Israel’s Office of the Chief Scientist. This is already the eighth year that the company has received a grant of support from the Office of the Chief Scientist. According to the company, the funds will be put towards the continued development of NurOwn, the company’s mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases and the Phase II clinical program in amyotrophic lateral sclerosis (ALS). The Office of the Chief Scientist has provided grants worth $4.1 since 2007 to BrainStorm to support the development of NurOwn.
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Facebook comments